Mindset Pharma has been granted a U.S. patent for its lead candidate drug, MSP-1014.
MSP-1014 and MSP-1009 are novel analogues of psilocybin that demonstrated improved efficacy and safety profiles in pre-clinical studies.
Yet, in a patent law twist, Reunion Neuroscience (formerly Field Trip) was already awarded a patent for the same compound in April of last year. FT-104 (informally known as “Isoprocin Glutarate”). Reunion’s patent titled “Tryptamine Prodrugs,” grants exclusive rights for the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including FT-104. The patent will provide protection until 2040.
So what happens when two companies are granted patents for the same compound? Good question. Graham Pechenik, patent attorney, comments on the conundrum in this thread:
What happens when two companies’ patents both cover the same drug?
Reunion Neuroscience’s lead RE104 = isoprocin glutarate, a prodrug of 4-OH-DiPT
Reunion $REUN has a granted patent claiming it
Today, Mindset Pharma $MSET received a notice of allowance on claims to it too
— Graham Pechenik (@calyxlaw) January 19, 2023
We’ll stay on this story to see which company comes out on top of this patent drama.
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for Mindset’s patent application number 17/833,341, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.” Included within this application is MSP-1014, its backup MSP-1009, as well as additional prodrug candidates that the Company classifies as belonging to Family 1.
MSP-1014 and MSP-1009 are novel analogues of psilocybin that demonstrated improved efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre-clinical studies. Also included in this patent application are multiple other tryptamine prodrug candidates and other psilocybin analogs. This application is one of a family of applications having a priority date of February 4, 2020.
“Since its inception, Mindset has been focused on discovering and developing novel therapeutics, because it is our view that they offer the greatest opportunity to help patients with unmet medical needs. Our early and consistent focus on novelty has created a valuable intellectual property (IP) portfolio,” said James Lanthier, CEO of Mindset Pharma. “Further, this focus on IP has already created value for Mindset, and today’s announcement is a good indication of the potential for additional returns for Mindset thanks to our ongoing focus on novel optimized psychedelic inspired medications.”
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic and non-psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.
For further information on Mindset, please visit our website at www.mindsetpharma.com.